The Relationship Between Gene Mutation and Pathological Type of Lung Cancer

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the relationship between gene mutation and pathological type of lung cancer, inspect and verify the consistency between homologous genes mutation in various pathologic type. Methods: Combined with the COSMIC and UniProt database, we obtained the reported overall big-sample mutation data of lung cancer and the protein sequences of the top 20 mutated genes, respectively. Analyze the data and cluster the protein sequences and then deduce the homologous gene. Ultimately, analyze the mutations of different pathological types of homologous genes. Results: TP53 (32.32%) has the highest mutation rate in lung cancer, followed by EGFR (29.12%). The copy number variability (CNV) of genes: KRAS, LRP1B, CDKN2A, KMT2C, FAT1, PIK3CA, RB1, ERBB4, GRIN2A and KDR between each pathological type is statically significant (P<0.05). The gene differential expression rate between adenocarcinoma and squamous carcinoma of gene TP53, KRAS, LRP1B, CDKN2A, STK11, FAT4, KMT2D, NFE2L2, KEAP1, PIK3CA, RB1, ERBB4, SMARCA4 and KDR are statistically significant (P<0.05). The similarity of the protein sequence of EGFR and ERBB4 can reach 93%, and FAT4 and FAT1 are 81%. For small cell carcinoma, there's no difference in CNV between the two groups of homologous genes, and no difference between FAT4 and FAT1 in adenocarcinoma. Conclusion: The CNV and gene expression of lung cancer-associated genes are relevant to pathologic types. GFR and ERBB4 are homologous, FAT4 and FAT1 are also among the top 20 mutation genes. Additionally, there's no difference in CNV between the two groups of small cell carcinoma, which is the same between FAT4 and FAT1 in adenocarcinoma.

Key words： lung cancer pathologic typing gene mutation

Received: 15 March 2018

PACS:

R734.2

Fund:the Funding of Hunan Provincial Department of Education; grant number: [2014] No.247; [2016] No.400

Corresponding Authors: ZHA Wen-ting. E-mail: 183259829@qq.com; LV Yuan. E-mail: 284792906@qq.com

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	PANG Feng-rui
	QU Fang
	WU Bin
	ZHA Wen-ting
	LV Yuan

Cite this article:

PANG Feng-rui,QU Fang,WU Bin, et al. The Relationship Between Gene Mutation and Pathological Type of Lung Cancer[J]. Chinese Journal of Biomedical Engineering, 2018, 27(2): 47-56.

URL:

http://manu32.magtech.com.cn/Jwk_zgswyx_en/EN/ OR http://manu32.magtech.com.cn/Jwk_zgswyx_en/EN/Y2018/V27/I2/47

[1] Siegel R, Naishadham D, Jemal A.Cancer statistics[J]. Ca-a Cancer Journal for Clinicians, 2012, 62(1): 10-29.
[2] Lemjabbar-Alaoui H, Hassan OU, Yang YW, et al.Lung cancer: Biology and treatment options[J]. Biochimica et Biophysica Acta, 2015, 1856(2): 189-210.
[3] Semenova EA, Nagel R, Berns A.Origins, genetic landscape, and emerging therapies of small cell lung cancer[J]. Genes & Development, 2015, 29(14): 1447-1462.
[4] Li Yan, Guo Qisen.Progress in maintenance of advanced non-small cell lung cancer[J]. Chinese Journal of Cancer Prevention and Treatment, 2014, 21(10): 800-804.
[5] Ryska A, Dziadziuszko R, Olszewski W, et al.Molecular diagnostics of lung cancer[J]. Magyar Onkológia, 2015, 59(3): 259-266.
[6] Marinov M, Mosa ASM, Yoo I, et al.Data-mining technologies for diabetes: A systematic review[J]. Journal of Diabetes Science and Technology, 2011, 5(6):1549-1556.
[7] Cheng PF, Dummer R, Levesque MP.Data mining the cancer genome atlas in the era of precision cancer medicine[J]. Swiss Medical Weekly, 2015, 145: w14183.
[8] Gonzalez GH, Tahsin T, Goodale BC, et al.Recent advances and emerging applications in text and data mining for biomedical discovery[J]. Briefings in Bioinformatics, 2016, 17(1): 33-42.
[9] Hammann F, Drewe J.Data mining for potential adverse drug-drug interactions[J]. Expert Opinion Drug Metabolism & Toxicology, 2014, 10(5): 665-671.
[10] Ellis MJ, Gillette M, Carr SA, et al.Connecting genomic alterations to cancer biology with proteomics: the NCI clinical proteomic tumor analysis consortium[J]. Cancer Discovery, 2013, 3(10): 1108-1112.
[11] Shtivelman E, Hensing T, Simon GR, et al.Molecular pathways and therapeutic targets in lung cancer[J]. Oncotarget, 2014, 5(6):1392-1433.
[12] Joudaki H, Rashidian A, Minaei-Bidgoli B, et al.Using data mining to detect health care fraud and abuse: A review of literature[J]. Global Journal of Health Science, 2015, 7(1):194-202.
[13] Tang Dongming, Zhu Qingxin, Fan Yang, et al.An effective method for cluster analysis of protein sequences[J]. Journal of Software, 2011, 22(8): 1827-1837.
[14] Xie Huijun, Yu ShaSha, Zhang Lele, et al. Comprehensive analysis of 16 known lung cancer gene mutations in Chinese population[J]. Advances in Modern Biomedicine, 2015, 15(33): 6449-6454.
[15] Gadepalli VS, Deb SP, Deb S, et al.Lung cancer stem cells, TP53 mutations and MDM2[J]. Subcellular Biochemistry, 2014, 85: 359-370.
[16] Mao C, Qiu LX, Liao RY, et al.KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies[J]. Lung Cancer, 2010, 69(3): 272-278.
[17] Wong KK, deLeeuw RJ, Dosanjh NS, et al. A comprehensive analysis of common copy-number variations in the human genome[J]. American Journal of Human Genetics, 2007, 80(1): 91-104.
[18] Yi Suqin, Zhuang Yuan, Zhu Weidong, et al.Analysis of KRAS gene mutation in non-small cell lung cancer[J]. Chinese Journal of Clinical Medicine (Electronic Edition), 2013, 7(20): 9111-9115.
[19] Jones PA.Functions of DNA methylation: islands, start sites, gene bodies and beyond[J]. Nature Reviews Genetics, 2012, 13(7): 484-492.